CliffBio
small molecule

VASOCON

NAPHAZOLINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameVASOCON
Active ingredientNAPHAZOLINE HYDROCHLORIDE
Strength0.1%
Dosage formSOLUTION/DROPS
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalMarch 1983
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.